{"id":959627,"date":"2026-05-07T07:29:03","date_gmt":"2026-05-07T11:29:03","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-to-deliver-presentations-at-multiple-medical-conferences-in-may-2026\/"},"modified":"2026-05-07T07:29:03","modified_gmt":"2026-05-07T11:29:03","slug":"alterity-therapeutics-to-deliver-presentations-at-multiple-medical-conferences-in-may-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-to-deliver-presentations-at-multiple-medical-conferences-in-may-2026\/","title":{"rendered":"Alterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">MELBOURNE, Australia and SAN FRANCISCO, May  07, 2026  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9Qfl4sAAFkzUdeEskEkulB700bO3-1XNJ_8hRoMfIRB_KTmeBc5X0eAkqBn_7ZyvPtpPG0r5fDy-0j_9q-RKfkWh55iXwq-bdS3x0TaGDuI=\" rel=\"nofollow\" target=\"_blank\"><u>Alterity Therapeutics<\/u><\/a> (ASX: ATH, NASDAQ: ATHE) (\u201cAlterity\u201d or \u201cthe Company\u201d), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that presentations related to the Company\u2019s development program in Multiple System Atrophy (MSA) will be delivered at multiple medical conferences in May 2026.<\/p>\n<p align=\"justify\">\n        <strong>The International Society for Magnetic Resonance in Medicine 2026 ISMRM and ISMRT Annual Meeting and Exhibition<\/strong>\n      <\/p>\n<ul>\n<li style=\"text-align:justify\">\n          <strong>Title: Quantitative Susceptibility Mapping Detects Progressive Iron Accumulation in Early MSA<\/strong><br \/>\n          <strong>(<\/strong>Abstract #03335)<\/li>\n<li style=\"text-align:justify\">Type: Oral Presentation<\/li>\n<li style=\"text-align:justify\">Presenter: Paula Trujillo, PhD, Research Assistant Professor, Department of Neurology, Vanderbilt University Medical Center<\/li>\n<li style=\"text-align:justify\">Date\/Time: Tuesday, May 12, 2026, 16:00-17:50 local time<\/li>\n<li style=\"text-align:justify\">Location: Cape Town, South Africa<\/li>\n<\/ul>\n<p align=\"justify\">\n        <strong>Movement Disorder Society of Australia and New Zealand (MDSANZ) Scientific Meeting<\/strong>\n      <\/p>\n<ul>\n<li style=\"text-align:justify\">\n          <strong>Title: Results from a Randomized, Double-Blind, Placebo-Controlled Study of ATH434 in MSA using CSF NfL as a Covariate<\/strong>\n        <\/li>\n<li style=\"text-align:justify\">Type: Poster Presentation<\/li>\n<li style=\"text-align:justify\">Presenter: Daniel Claassen, M.D., M.S., Professor of Neurology at Vanderbilt University Medical Center and Chief Medical Advisor for Alterity<\/li>\n<li style=\"text-align:justify\">Conference Dates: May 15-17, 2026<\/li>\n<li style=\"text-align:justify\">Location: Sydney, Australia<\/li>\n<\/ul>\n<p align=\"justify\">\n        <strong>MSA Symposium 2026<\/strong>\n      <\/p>\n<ul>\n<li style=\"text-align:justify\">\n          <strong>Title: ATH434 Clinical Update and Phase 3 Planning<\/strong>\n        <\/li>\n<li style=\"text-align:justify\">Type: Oral Presentation<\/li>\n<li style=\"text-align:justify\">Presenter: David Stamler, M.D., CEO of Alterity Therapeutics<\/li>\n<li style=\"text-align:justify\">Date\/Time: Monday, May 18, 2026, 16.15-17.00 local time<\/li>\n<li style=\"text-align:justify\">Location: London, UK<\/li>\n<\/ul>\n<p align=\"justify\">\n        <strong>About Alterity Therapeutics Limited <\/strong>\n      <\/p>\n<p align=\"justify\">Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living\u00a0with neurodegenerative diseases. The Company is focused on developing disease modifying therapies in Multiple System Atrophy (MSA) and related Parkinsonian disorders. Alterity is preparing to initiate a Phase 3 pivotal trial in MSA, a rare and rapidly progressive disease. ATH434, the Company\u2019s lead asset, has demonstrated clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 clinical trial in participants with MSA. Alterity has further reported positive data in its open label Phase 2 clinical trial in participants with advanced MSA. In addition, Alterity has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=MiOwPgxMSnx5JwW0yNUFMaZZyAld3iLkQhDcnUQXlcfs1O9VHknhrwRKtK7h25p4oZESHC0Qtqc6FoBz869JZN6loKYHXknOXGFlCI8-1tQ=\" rel=\"nofollow\" target=\"_blank\"><u>https:\/\/alteritytx.com<\/u><\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Authorisation &amp; Additional information<\/strong><br \/>\n        <br \/>This announcement was authorized by the David Stamler, CEO of Alterity Therapeutics Limited.<\/p>\n<p align=\"justify\">\n        <strong>Contacts:<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <strong>Investors:<\/strong><br \/>\n        <br \/>Elyse Shapiro<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=sYzRX-W8qI0ekHATJ8AvUoLMS3FL0P166BKC2W2aG0j1cNzB7WxehXFGWdWQx9CzWPD4X6Tqo_qLsX0kMQ0s6bOSbZy4YAbzSLMIoSy6gP0=\" rel=\"nofollow\" target=\"_blank\"><u>ir@alteritytx.com<\/u><\/a><\/p>\n<p align=\"justify\">Remy Bernarda<br \/>Investor Relations Advisory Solutions<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=sYzRX-W8qI0ekHATJ8AvUu6Z6ZcOUODqmKKG4uuWiRwcxDOBdrcTCX-3loDVQKjzoQHfU8Vge1-bIX3Yr6Rjpmr33cXaOSBQsZZZBDOHvYQ=\" rel=\"nofollow\" target=\"_blank\"><u>ir@alteritytx.com<\/u><\/a><br \/>+1 (415) 203-6386<\/p>\n<p align=\"justify\">\n        <strong>Media<\/strong><br \/>\n        <br \/>Casey McDonald<br \/>Tiberend Strategic Advisors, Inc.<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=DcujfzklBtqjJAx-uRxJiq5LAI8hqBDbqfiLrz0hU7wRA6-ZRLyGRbtf9wF51xiq7iV95Dgh2F30Xhq8uybnUnnaHtChpTnMUiX5i8lcHjo=\" rel=\"nofollow\" target=\"_blank\"><u>cmcdonald@tiberend.com<\/u><\/a><br \/>+1 (646) 577-8520<\/p>\n<p align=\"justify\">\n        <strong>Forward Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <em>This press release contains &#8220;forward-looking statements&#8221; within the meaning of section 27A of the Securities Act of 1933 and section<\/em><br \/>\n        <em>21E<\/em><br \/>\n        <em>of<\/em><br \/>\n        <em>the<\/em><br \/>\n        <em>Securities<\/em><br \/>\n        <em>Exchange<\/em><br \/>\n        <em>Act<\/em><br \/>\n        <em>of<\/em><br \/>\n        <em>1934.<\/em><br \/>\n        <em>The<\/em><br \/>\n        <em>Company<\/em><br \/>\n        <em>has<\/em><br \/>\n        <em>tried<\/em><br \/>\n        <em>to<\/em><br \/>\n        <em>identify<\/em><br \/>\n        <em>such<\/em><br \/>\n        <em>forward-looking<\/em><br \/>\n        <em>statements<\/em><br \/>\n        <em>by<\/em><br \/>\n        <em>use of such words as &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;hopes,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;could,&#8221; &#8220;may,&#8221; &#8220;evidences&#8221; and &#8220;estimates,&#8221; and other similar expressions, but these words are not the exclusive means of identifying such<\/em><br \/>\n        <em>statements.<\/em>\n      <\/p>\n<p align=\"justify\">\n        <em>Important<\/em><br \/>\n        <em>factors<\/em><br \/>\n        <em>that<\/em><br \/>\n        <em>could<\/em><br \/>\n        <em>cause<\/em><br \/>\n        <em>actual<\/em><br \/>\n        <em>results<\/em><br \/>\n        <em>to<\/em><br \/>\n        <em>differ<\/em><br \/>\n        <em>materially<\/em><br \/>\n        <em>from<\/em><br \/>\n        <em>those<\/em><br \/>\n        <em>indicated<\/em><br \/>\n        <em>by<\/em><br \/>\n        <em>such<\/em><br \/>\n        <em>forward-looking<\/em><br \/>\n        <em>statements are<\/em><br \/>\n        <em>described<\/em><br \/>\n        <em>in<\/em><br \/>\n        <em>the<\/em><br \/>\n        <em>sections<\/em><br \/>\n        <em>titled<\/em><br \/>\n        <em>\u201cRisk<\/em><br \/>\n        <em>Factors\u201d<\/em><br \/>\n        <em>in<\/em><br \/>\n        <em>the<\/em><br \/>\n        <em>Company\u2019s<\/em><br \/>\n        <em>filings<\/em><br \/>\n        <em>with<\/em><br \/>\n        <em>the<\/em><br \/>\n        <em>SEC,<\/em><br \/>\n        <em>including<\/em><br \/>\n        <em>its<\/em><br \/>\n        <em>most<\/em><br \/>\n        <em>recent<\/em><br \/>\n        <em>Annual<\/em><br \/>\n        <em>Report on<\/em><br \/>\n        <em>Form<\/em><br \/>\n        <em>20-F<\/em><br \/>\n        <em>as<\/em><br \/>\n        <em>well<\/em><br \/>\n        <em>as<\/em><br \/>\n        <em>reports<\/em><br \/>\n        <em>on<\/em><br \/>\n        <em>Form<\/em><br \/>\n        <em>6-K,<\/em><br \/>\n        <em>including,<\/em><br \/>\n        <em>but<\/em><br \/>\n        <em>not<\/em><br \/>\n        <em>limited<\/em><br \/>\n        <em>to<\/em><br \/>\n        <em>the<\/em><br \/>\n        <em>following:<\/em><br \/>\n        <em>statements<\/em><br \/>\n        <em>relating<\/em><br \/>\n        <em>to<\/em><br \/>\n        <em>the<\/em><br \/>\n        <em>Company&#8217;s drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company&#8217;s<\/em><br \/>\n        <em>drug<\/em><br \/>\n        <em>development<\/em><br \/>\n        <em>program,<\/em><br \/>\n        <em>including,<\/em><br \/>\n        <em>but<\/em><br \/>\n        <em>not<\/em><br \/>\n        <em>limited<\/em><br \/>\n        <em>to,<\/em><br \/>\n        <em>ATH434,<\/em><br \/>\n        <em>and<\/em><br \/>\n        <em>any<\/em><br \/>\n        <em>other<\/em><br \/>\n        <em>statements<\/em><br \/>\n        <em>that<\/em><br \/>\n        <em>are<\/em><br \/>\n        <em>not<\/em><br \/>\n        <em>historical facts.<\/em><br \/>\n        <em>Such<\/em><br \/>\n        <em>statements<\/em><br \/>\n        <em>involve<\/em><br \/>\n        <em>risks<\/em><br \/>\n        <em>and<\/em><br \/>\n        <em>uncertainties,<\/em><br \/>\n        <em>including,<\/em><br \/>\n        <em>but<\/em><br \/>\n        <em>not<\/em><br \/>\n        <em>limited<\/em><br \/>\n        <em>to,<\/em><br \/>\n        <em>those<\/em><br \/>\n        <em>risks<\/em><br \/>\n        <em>and<\/em><br \/>\n        <em>uncertainties<\/em><br \/>\n        <em>relating<\/em><br \/>\n        <em>to<\/em><br \/>\n        <em>the difficulties<\/em><br \/>\n        <em>or<\/em><br \/>\n        <em>delays<\/em><br \/>\n        <em>in<\/em><br \/>\n        <em>financing,<\/em><br \/>\n        <em>development,<\/em><br \/>\n        <em>testing,<\/em><br \/>\n        <em>regulatory<\/em><br \/>\n        <em>approval,<\/em><br \/>\n        <em>production<\/em><br \/>\n        <em>and<\/em><br \/>\n        <em>marketing<\/em><br \/>\n        <em>of<\/em><br \/>\n        <em>the<\/em><br \/>\n        <em>Company\u2019s<\/em><br \/>\n        <em>drug components,<\/em><br \/>\n        <em>including,<\/em><br \/>\n        <em>but<\/em><br \/>\n        <em>not<\/em><br \/>\n        <em>limited<\/em><br \/>\n        <em>to,<\/em><br \/>\n        <em>ATH434,<\/em><br \/>\n        <em>the<\/em><br \/>\n        <em>ability<\/em><br \/>\n        <em>of<\/em><br \/>\n        <em>the<\/em><br \/>\n        <em>Company<\/em><br \/>\n        <em>to<\/em><br \/>\n        <em>procure<\/em><br \/>\n        <em>additional<\/em><br \/>\n        <em>future<\/em><br \/>\n        <em>sources<\/em><br \/>\n        <em>of<\/em><br \/>\n        <em>financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company&#8217;s drug compounds, including, but not limited<\/em><br \/>\n        <em>to,<\/em><br \/>\n        <em>ATH434,<\/em><br \/>\n        <em>that<\/em><br \/>\n        <em>could<\/em><br \/>\n        <em>slow<\/em><br \/>\n        <em>or prevent products<\/em><br \/>\n        <em>coming<\/em><br \/>\n        <em>to<\/em><br \/>\n        <em>market,<\/em><br \/>\n        <em>the uncertainty<\/em><br \/>\n        <em>of obtaining patent protection<\/em><br \/>\n        <em>for<\/em><br \/>\n        <em>the<\/em><br \/>\n        <em>Company&#8217;s intellectual<\/em><br \/>\n        <em>property<\/em><br \/>\n        <em>or<\/em><br \/>\n        <em>trade<\/em><br \/>\n        <em>secrets, the uncertainty of successfully enforcing the Company\u2019s patent rights and the uncertainty of the Company freedom to operate.<\/em>\n      <\/p>\n<p align=\"justify\">\n        <em>Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks<\/em><br \/>\n        <em>only<\/em><br \/>\n        <em>as<\/em><br \/>\n        <em>of<\/em><br \/>\n        <em>the<\/em><br \/>\n        <em>date<\/em><br \/>\n        <em>on<\/em><br \/>\n        <em>which<\/em><br \/>\n        <em>it<\/em><br \/>\n        <em>is<\/em><br \/>\n        <em>made.<\/em><br \/>\n        <em>We<\/em><br \/>\n        <em>undertake<\/em><br \/>\n        <em>no<\/em><br \/>\n        <em>obligation<\/em><br \/>\n        <em>to<\/em><br \/>\n        <em>publicly<\/em><br \/>\n        <em>update<\/em><br \/>\n        <em>any<\/em><br \/>\n        <em>forward-looking<\/em><br \/>\n        <em>statement, whether<\/em><br \/>\n        <em>written<\/em><br \/>\n        <em>or<\/em><br \/>\n        <em>oral,<\/em><br \/>\n        <em>that<\/em><br \/>\n        <em>may<\/em><br \/>\n        <em>be<\/em><br \/>\n        <em>made<\/em><br \/>\n        <em>from<\/em><br \/>\n        <em>time<\/em><br \/>\n        <em>to<\/em><br \/>\n        <em>time,<\/em><br \/>\n        <em>whether<\/em><br \/>\n        <em>as<\/em><br \/>\n        <em>a<\/em><br \/>\n        <em>result<\/em><br \/>\n        <em>of<\/em><br \/>\n        <em>new<\/em><br \/>\n        <em>information,<\/em><br \/>\n        <em>future<\/em><br \/>\n        <em>developments<\/em><br \/>\n        <em>or otherwise.<\/em>\n      <\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxNTE5MSM3NTg5MjIxIzIyNTY3MTM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NGZlODhhMTAtM2ZkMy00NmJhLTkxNGItYjRmNmViZDhiZmZlLTEyNjgyNjItMjAyNi0wNS0wNy1lbg==\/tiny\/ALTERITY-THERAPEUTICS-LIMITED.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>MELBOURNE, Australia and SAN FRANCISCO, May 07, 2026 (GLOBE NEWSWIRE) &#8212; Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (\u201cAlterity\u201d or \u201cthe Company\u201d), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that presentations related to the Company\u2019s development program in Multiple System Atrophy (MSA) will be delivered at multiple medical conferences in May 2026. The International Society for Magnetic Resonance in Medicine 2026 ISMRM and ISMRT Annual Meeting and Exhibition Title: Quantitative Susceptibility Mapping Detects Progressive Iron Accumulation in Early MSA (Abstract #03335) Type: Oral Presentation Presenter: Paula Trujillo, PhD, Research Assistant Professor, Department of Neurology, Vanderbilt University Medical Center Date\/Time: Tuesday, May 12, 2026, 16:00-17:50 local time Location: Cape Town, South Africa Movement Disorder Society &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-to-deliver-presentations-at-multiple-medical-conferences-in-may-2026\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Alterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-959627","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Alterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-to-deliver-presentations-at-multiple-medical-conferences-in-may-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"MELBOURNE, Australia and SAN FRANCISCO, May 07, 2026 (GLOBE NEWSWIRE) &#8212; Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (\u201cAlterity\u201d or \u201cthe Company\u201d), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that presentations related to the Company\u2019s development program in Multiple System Atrophy (MSA) will be delivered at multiple medical conferences in May 2026. The International Society for Magnetic Resonance in Medicine 2026 ISMRM and ISMRT Annual Meeting and Exhibition Title: Quantitative Susceptibility Mapping Detects Progressive Iron Accumulation in Early MSA (Abstract #03335) Type: Oral Presentation Presenter: Paula Trujillo, PhD, Research Assistant Professor, Department of Neurology, Vanderbilt University Medical Center Date\/Time: Tuesday, May 12, 2026, 16:00-17:50 local time Location: Cape Town, South Africa Movement Disorder Society &hellip; Continue reading &quot;Alterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-to-deliver-presentations-at-multiple-medical-conferences-in-may-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-07T11:29:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxNTE5MSM3NTg5MjIxIzIyNTY3MTM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alterity-therapeutics-to-deliver-presentations-at-multiple-medical-conferences-in-may-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alterity-therapeutics-to-deliver-presentations-at-multiple-medical-conferences-in-may-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Alterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026\",\"datePublished\":\"2026-05-07T11:29:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alterity-therapeutics-to-deliver-presentations-at-multiple-medical-conferences-in-may-2026\\\/\"},\"wordCount\":750,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alterity-therapeutics-to-deliver-presentations-at-multiple-medical-conferences-in-may-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxNTE5MSM3NTg5MjIxIzIyNTY3MTM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alterity-therapeutics-to-deliver-presentations-at-multiple-medical-conferences-in-may-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alterity-therapeutics-to-deliver-presentations-at-multiple-medical-conferences-in-may-2026\\\/\",\"name\":\"Alterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alterity-therapeutics-to-deliver-presentations-at-multiple-medical-conferences-in-may-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alterity-therapeutics-to-deliver-presentations-at-multiple-medical-conferences-in-may-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxNTE5MSM3NTg5MjIxIzIyNTY3MTM=\",\"datePublished\":\"2026-05-07T11:29:03+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alterity-therapeutics-to-deliver-presentations-at-multiple-medical-conferences-in-may-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alterity-therapeutics-to-deliver-presentations-at-multiple-medical-conferences-in-may-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alterity-therapeutics-to-deliver-presentations-at-multiple-medical-conferences-in-may-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxNTE5MSM3NTg5MjIxIzIyNTY3MTM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxNTE5MSM3NTg5MjIxIzIyNTY3MTM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alterity-therapeutics-to-deliver-presentations-at-multiple-medical-conferences-in-may-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Alterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Alterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-to-deliver-presentations-at-multiple-medical-conferences-in-may-2026\/","og_locale":"en_US","og_type":"article","og_title":"Alterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026 - Market Newsdesk","og_description":"MELBOURNE, Australia and SAN FRANCISCO, May 07, 2026 (GLOBE NEWSWIRE) &#8212; Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (\u201cAlterity\u201d or \u201cthe Company\u201d), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that presentations related to the Company\u2019s development program in Multiple System Atrophy (MSA) will be delivered at multiple medical conferences in May 2026. The International Society for Magnetic Resonance in Medicine 2026 ISMRM and ISMRT Annual Meeting and Exhibition Title: Quantitative Susceptibility Mapping Detects Progressive Iron Accumulation in Early MSA (Abstract #03335) Type: Oral Presentation Presenter: Paula Trujillo, PhD, Research Assistant Professor, Department of Neurology, Vanderbilt University Medical Center Date\/Time: Tuesday, May 12, 2026, 16:00-17:50 local time Location: Cape Town, South Africa Movement Disorder Society &hellip; Continue reading \"Alterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-to-deliver-presentations-at-multiple-medical-conferences-in-may-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-07T11:29:03+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxNTE5MSM3NTg5MjIxIzIyNTY3MTM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-to-deliver-presentations-at-multiple-medical-conferences-in-may-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-to-deliver-presentations-at-multiple-medical-conferences-in-may-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Alterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026","datePublished":"2026-05-07T11:29:03+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-to-deliver-presentations-at-multiple-medical-conferences-in-may-2026\/"},"wordCount":750,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-to-deliver-presentations-at-multiple-medical-conferences-in-may-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxNTE5MSM3NTg5MjIxIzIyNTY3MTM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-to-deliver-presentations-at-multiple-medical-conferences-in-may-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-to-deliver-presentations-at-multiple-medical-conferences-in-may-2026\/","name":"Alterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-to-deliver-presentations-at-multiple-medical-conferences-in-may-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-to-deliver-presentations-at-multiple-medical-conferences-in-may-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxNTE5MSM3NTg5MjIxIzIyNTY3MTM=","datePublished":"2026-05-07T11:29:03+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-to-deliver-presentations-at-multiple-medical-conferences-in-may-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-to-deliver-presentations-at-multiple-medical-conferences-in-may-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-to-deliver-presentations-at-multiple-medical-conferences-in-may-2026\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxNTE5MSM3NTg5MjIxIzIyNTY3MTM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxNTE5MSM3NTg5MjIxIzIyNTY3MTM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-to-deliver-presentations-at-multiple-medical-conferences-in-may-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Alterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/959627","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=959627"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/959627\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=959627"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=959627"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=959627"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}